Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed (R) Angioimmunoblastic T-cell Lymphoma (AT): A Single-arm, Multicenter Phase II Study(SCRAT)

NCT04831710 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04831710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04831710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed (R) Angioimmunoblastic T-cell Lymphoma (AT): A Single-arm, Multicenter Phase II Study(SCRAT)
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
April 15, 2021
Completion date
April 15, 2023
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma